Goldman Sachs
IMUX icon

Goldman Sachs’s Immunic IMUX Stock Holding History

Goldman Sachs’s Portfolio IMUX Stock Details IMUX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-250
Closed -$404K – 7239
2015
Q3 		$404K Buy
+250
New +$1.25M ﹤0.01% 5348

Other funds holding IMUX

APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Goldman Sachs's IMUX Position: Q1 2026 in Review

Goldman Sachs opened a new position in Immunic (IMUX) in Q1 2026: 14,977 shares worth $166K. The stake represents ﹤0.01% of the portfolio and ranks #6130 among its holdings. This is a return to the name: Goldman Sachs previously reported a position in IMUX as recently as Q1 2024.

Goldman Sachs first reported a position in IMUX in Q2 2014 and has held it in 31 quarters since. The position peaked at $2.78M in Q1 2022. 75 funds tracked by Wall St. Rank hold IMUX as of Q1 2026.

  • Goldman Sachs held 14,977 shares of Immunic worth $166K as of Q1 2026.
  • Immunic was a new Goldman Sachs position in Q1 2026.
  • Immunic made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #6130 holding.
  • Goldman Sachs first reported a position in Immunic in Q2 2014 and has held it in 31 quarters since.
  • Goldman Sachs's Immunic position peaked at $2.78M in Q1 2022.
  • 75 funds tracked by Wall St. Rank held Immunic as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.